Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

Yang, Yunpeng; Pan, Jianji; Wang, Hui; Zhao, Yuanyuan; Qu, Shenhong; Chen, Nianyong; Chen, Xiaozhong; Sun, Yan; He, Xiaohui; Hu, Chaosu; Lin, Lizhu; Yu, Qitao; Wang, Siyang; Wang, Guihua; Lei, Feng; Wen, Jiyu; Yang, Kunyu; Lin, Zhixiong; Guo, Ye; Chen, Shaoqing; Huang, Xiaoming; Wu, Yanjie; Liang, Liang; Chen, Chenqi; Bai, Fan; Ma, Xiaopeng; Zhang, Yun; Leaw, Shiangjiin; Zhang, Li; Fang, Wenfeng

doi:10.1016/j.ccell.2023.04.014

articleCancer CellMay 18, 2023HYBRID OA

Tislelizumab plus chemotherapy as first-line treatment for recurrent or metastatic nasopharyngeal cancer: A multicenter phase 3 trial (RATIONALE-309)

YYYunpeng Yang JPJianji Pan HWHui Wang YZYuanyuan Zhao SQShenhong Qu

Sun Yat-sen University Cancer Center · Sun Yat-sen University · +24 more institutions

PubMed

Indexed incrossrefpubmed

Abstract

Checkpoint inhibitors are effective in recurrent/metastatic nasopharyngeal cancer (R/M NPC). RATIONALE-309 (NCT03924986) randomized 263 treatment-naive R/M NPC patients to tislelizumab or placebo every 3 weeks (Q3W), plus chemotherapy (Q3W for 4–6 cycles). At interim analysis, progression-free survival (PFS) was significantly longer with tislelizumab-chemotherapy versus placebo-chemotherapy (hazard ratio: 0.52; 95% confidence interval: 0.38, 0.73; p

Citation impact

210

total citations

FWCI: 45.51
Percentile: 100%
References: 24

Citations per year

Authors

30

Topics & keywords

Topics

Keywords

Nasopharyngeal cancer
Chemotherapy
Medicine
Oncology
Internal medicine
Cancer
Multicenter trial
Phases of clinical research

UN Sustainable Development Goals

Good health and well-being

No related works found for this paper.